YOLFTbeta
60 Degrees Pharmaceuticals, Inc. Common Stock

60 Degrees Pharmaceuticals, Inc. Common Stock

SXTP · NASDAQ · Healthcare / Biotechnology

0.5179USD-0.00 (-0.19%)

Price History

Full chart

Market Stats

Previous Close0.5189
Open0.4995
Day Range0.486 – 0.5189
52-Week Range0.84 – 7.36
Volume24.47K
Market Cap4.40M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.67
Dividend Yield0.00%
Beta2.54
50-Day Avg1.14
200-Day Avg1.97

About

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Geoffrey Stuart Dow Ph.D.
  • Employees3
  • Headquarters1025 Connecticut Avenue NW, Washington, DC, United States, 20036, USA
  • Websitehttps://www.60degreespharma.com

Leadership

  • Dr. Geoffrey Stuart Dow Ph.D.Chairman, CEO & President · b. 1974
  • Mr. Tyrone MillerCFO & Treasurer · b. 1975
  • Ms. Kristen LandonChief Commercial Officer · b. 1967
  • Dr. Bryan SmithChief Medical Officer · b. 1966

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.18M1.16M223.21K253.57K607.57K1.01M
Growth (%)--46.81%-80.76%+13.60%+139.61%+65.49%
Cost of Revenue702.99K850.74K432.37K474.55K384.76K781.70K
Gross Profit1.48M309.60K-209.16K-220.98K222.81K223.78K
Gross Margin67.77%26.68%-93.71%-87.15%36.67%22.26%
Operating Expense1.90M1.43M1.54M4.93M9.94M7.98M
Operating Income-418.13K-1.12M-1.75M-5.15M-9.71M-7.76M
Operating Margin-19.17%-96.88%-784.22%-2032.78%-1598.97%-771.64%
EBITDA-341.17K-1.01M-2.11M-1.43M-7.88M-7.28M
EBITDA Margin-15.64%-87.46%-944.92%-562.58%-1297.58%-723.80%
Net Income-3.03M-4.25M-6.18M-3.77M-7.95M-7.37M
Net Income Margin-139.08%-366.42%-2769.49%-1485.06%-1308.01%-732.82%
R&D806.68K5.51M525.56K691.77K4.99M2.11M
R&D as % of Total Revenue36.98%474.94%235.46%272.81%820.73%209.47%
Interest Expense2.68M3.17M3.99M2.29M7.91K7.80K
Interest Expense % of Total Revenue122.79%273.43%1787.28%901.77%1.30%0.78%

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.61M1.39M1.30M7.78M5.76M5.37M
Total Liabilities20.68M19.55M25.45M2.99M1.80M1.99M
Total Equity-17.50M-17.58M-23.58M4.87M4.04M3.46M
Cash191.70K115.40K264.87K2.14M1.66M1.51M
Total Debt15.92M18.80M22.42M172.67K155.89K152.78K
Net Debt15.73M18.69M22.15M-1.97M-1.50M-1.36M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-167.30K-649.11K-1.01M-4.54M-5.65M-6.85M
Investing Cash Flow-70.98K-35.39K-60.13K-115.89K-1.89M254.92K
Financing Cash Flow277.36K611.23K1.22M6.47M7.05M6.44M
Capital Expenditure70.98K35.39K60.13K115.89K181.11K218.08K
Free Cash Flow-238.28K-684.50K-1.07M-4.66M-5.83M-7.07M
FCF to OCF142.43%105.45%105.95%102.55%103.21%103.18%

Earnings

Report DateAug 30, 2023Nov 20, 2023Feb 28, 2024May 15, 2024Aug 14, 2024Nov 14, 2024Feb 26, 2025May 15, 2025Aug 13, 2025Nov 13, 2025Mar 30, 2026Mar 31, 2026Aug 14, 2026Nov 12, 2026
EPS Estimate0.00228.00-0.14-52.80-33.60-17.40-0.18-1.31-4.96-1.84-2.00-0.99-0.74-0.73
EPS Actual-1.10184.80-0.34-31.54-84.60-17.35-2.16-1.56-4.33-2.53-8.17-1.21-0.90-
Surprise--18.95%-146.43%40.27%-151.79%0.29%-1100.00%-19.08%12.70%-37.50%-308.50%-22.65%-21.62%-
Timing-After-hours-After-hoursPre-marketAfter-hours-Pre-marketAfter-hoursAfter-hoursAfter-hours-After-hours-

Key Statistics & Ratios

Market Cap4.40M
Enterprise Value12.74M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.62
Price / Book0.00
EPS-2.67
Book Value-2.62
Revenue (TTM)1.21M
Gross Profit (TTM)-2.06M
EBITDA-8.50M
Profit Margin0.00%
Operating Margin-1092.41%
Return on Equity-332.85%
Return on Assets-127.11%
Shares Outstanding3.52M
Shares Float2.44M
Beta2.54
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 3.70
  • Strong Buy
    1

Ownership Breakdown

Institutions
17.11%
Insiders
19.39%
Retail / Other
63.50%

Top Institutional Holders

  • Kathmere Capital Management, LLC
    265.10K7.54%
  • UBS Group AG
    31.41K0.89%
  • Citadel Advisors Llc
    22.36K0.64%
  • Geode Capital Management, LLC
    16.30K0.46%
  • Kovack Advisors Inc
    15.00K0.43%
  • Barclays PLC
    1.86K0.05%
  • Goss Wealth Management LLC
    500.00%
  • Advisor Group Holdings, Inc.
    250.00%
  • Citigroup Inc
    10.00%
  • Tower Research Capital LLC
    00.00%
  • TWIN PEAKS WEALTH ADVISORS LLC
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    14.38K0.41%

Stock Splits

  • Jan 20, 20261:4
  • Feb 24, 20251:5
  • Aug 12, 20241:12